HIV Treatments in DevelopmentIDWeek

Extensively Drug-Resistant HIV Yields to a New Drug: Ibalizumab

Jacob Lalezari, M.D., and Daniel Kuritzkes, M.D.
Jacob Lalezari, M.D. (left), with Daniel Kuritzkes, M.D., discusses new ibalizumab study results during a press conference at IDWeek 2016 in New Orleans, Louisiana, on Oct. 28Myles Helfand/
    Myles Helfand

    Myles Helfand


    Myles Helfand is the executive editor and general manager of TheBody/TheBodyPro.